EDAP TMS S.A., each representing One Ordinary Share (EDAP): Price and Financial Metrics


EDAP TMS S.A., each representing One Ordinary Share (EDAP)

Today's Latest Price: $4.32 USD

0.08 (1.89%)

Updated Sep 23 4:00pm

Add EDAP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 138 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

EDAP Stock Summary

  • EDAP's current price/earnings ratio is 75.18, which is higher than 89.21% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for EDAP is currently 32.57, higher than 89% of US stocks with positive operating cash flow.
  • Over the past twelve months, EDAP has reported earnings growth of 88.01%, putting it ahead of 87.26% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Edap Tms Sa, a group of peers worth examining would be DESP, AVNW, PERI, ITT, and VIVO.
  • Visit EDAP's SEC page to see the company's official filings. To visit the company's web site, go to www.edap-tms.com.
EDAP Daily Price Range
EDAP 52-Week Price Range

EDAP Stock Price Chart Technical Analysis Charts


EDAP Price/Volume Stats

Current price $4.32 52-week high $5.39
Prev. close $4.24 52-week low $1.46
Day low $4.20 Volume 154,488
Day high $4.42 Avg. volume 111,622
50-day MA $3.54 Dividend yield N/A
200-day MA $3.20 Market Cap 125.27M

EDAP TMS S.A., each representing One Ordinary Share (EDAP) Company Bio


EDAP TMS S.A. develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases worldwide. The company was founded in 1979 and is based in Vaulx-en-Velin, France.

EDAP Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$4.32$2.73 -36%

We started the process of determining a valid price forecast for Edap Tms Sa with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Edap Tms Sa ranked in the 34th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 35.33%. As for the metrics that stood out in our discounted cash flow analysis of Edap Tms Sa, consider:

  • The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately only 17.54% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than merely 0% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-37%
1%-36%
2%-36%
3%-35%
4%-34%
5%-34%

Want more companies with a valuation profile/forecast similar to that of Edap Tms Sa? See NVS, CAH, GILD, LMAT, and OSMT.


EDAP Latest News Stream


Event/Time News Detail
Loading, please wait...

EDAP Latest Social Stream


Loading social stream, please wait...

View Full EDAP Social Stream

Latest EDAP News From Around the Web

Below are the latest news stories about Edap Tms Sa that investors may wish to consider to help them evaluate EDAP as an investment opportunity.

EDAP Set For Long-Term Growth

EDAP (EDAP) is surviving the drought of hospitals buying new stuff as a result of the pandemic being quite a bit better than many would have thought, which is why their share price has recovered nicely after encouraging Q2 results: We wrote in October last year that the company was...

Shareholders Unite on Seeking Alpha | September 16, 2020

EDAP Hosting Key Opinion Leader Call on Focal One® and ExactVu™

Call to be Held Tuesday, September 22nd @ 8am Eastern TimeLYON, France, September 15, 2020 \-- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will host a key opinion leader (KOL) call on its two lead commercial products, Focal One® and ExactVu™, on Tuesday, September 22nd at 8am Eastern Time.The call will feature a presentation by Key Opinion Leaders (KOL) Brian Miles, MD (Houston Methodist) and Laurence Klotz, MD (Sunnybrook Health Sciences Centre) who will discuss the opportunity for the Focal One® High Intensity Focused Ultrasound (HIFU) system and the ExactVu™ micro-ultrasound. Drs. Miles and Klotz will be available to answer questions at the conclusion of the call.EDAP TMS's management team will also give an update o...

Yahoo | September 15, 2020

EDAP Announces Presentation at the HC Wainwright Virtual 22nd Annual Global Investment Conference

LYON, France, September 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held September 14-15, 2020.  Presentation details Date: Tuesday, September 15 Time: 10:30am EDT Webcast: https://wsw.com/webcast/hcw7/edap/1581034The webcast will be archived and available for replay for a period of 90 days.About EDAP TMS SAA recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modaliti...

Yahoo | September 9, 2020

EDAP Announces First Patients Treated in Phase 2 Study of Focal One for the Treatment of Deep Invasive Endometriosis

·  First patients already treated as recruitment acceleratesLYON, France, September 3, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first two patients have been treated in the company’s Phase 2 clinical trial assessing Focal One® High Intensity Focused Ultrasound (HIFU) as a potential treatment for deep rectal endometriosis. A total of 38 women will be enrolled in the study and treated at five major hospitals and assessed over a six-month follow-up period. Follow-up of these patients will evaluate the safety and efficacy of HIFU for this pathology. Additional patients continue to be enrolled.Pr. Gil Dubernard, Head of the Gynecologic Department, Croix-Rousse University Hospital, Lyon, and lead investigator, commented, ...

Yahoo | September 3, 2020

EDAP Reports Second Quarter 2020 Results and Provides Operational Update

* Completed multiple Focal One sales to renowned U.S. and international health care institutions, including multiple Focal One™-ExactVu™ bundled sales * Announced first two U.S. publications in Journal of Urology detailing positive outcomes from U.S. studies of HIFU for the successful partial-gland ablation of prostate tissue * Maintained a strong cash position of EUR 15.7 million (USD 17.7 million) as of June 30, 2020 * Company to host a conference call tomorrow, August 27th, at 8:30 am EDT LYON, France, August 26, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the second quarter of 2020 and provided an update on strategic and operational developments. Marc Oczachowski, EDAP's Chairm...

Yahoo | August 26, 2020

Read More 'EDAP' Stories Here

EDAP Price Returns

1-mo 33.54%
3-mo 68.78%
6-mo 85.41%
1-year -4.21%
3-year 46.94%
5-year -23.54%
YTD -2.48%
2019 139.46%
2018 -35.54%
2017 -12.50%
2016 -20.58%
2015 77.25%

Continue Researching EDAP

Here are a few links from around the web to help you further your research on Edap Tms Sa's stock as an investment opportunity:

Edap Tms Sa (EDAP) Stock Price | Nasdaq
Edap Tms Sa (EDAP) Stock Quote, History and News - Yahoo Finance
Edap Tms Sa (EDAP) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7142 seconds.